PKP triple procedure with a 25G is a safe treatment option

Article

Penetrating keratoplasty (PKP) triple procedures with a 25G system is a safe and effective treatment option.

Penetrating keratoplasty (PKP) triple procedures with a 25G system is a safe and effective treatment option, claims a study in the journal Cornea.

Dr Shiro Higaki et al., Department of Ophthalmology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan, divided 30 patients into three groups. The groups were 12 eyes of 12 patients in the PKP group that underwent 25G vitrectomy, 9 eyes and 9 patients that underwent 20G vitrectomy and 9 eyes of 9 patients in the non-core vitrectomy group who underwent PKP without core vitrectomy.

The success rates of the IOL implantation were 97.1%, 88.9% and 66.7% for the 25G, 20G, and non-core vitrectomy groups, respectively. At 69 minutes for an average operation time the 25G group demonstrated the shortest time, compared to 82 minutes, and 90 minutes in the 20G group and the non-core vitrectomy group, respectively.

The PKP triple procedure with the 25G system offers a higher success rate of IOL implantation and significantly reduced operation time compared to 20G and non-core vitrectomy.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.